WELCOME TO The Biotechnology REPORT
Oxford Genetics Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy, Medical
QIAGEN | January 11, 2023
QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation.
QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector.
Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...
GlobeNewswire | September 28, 2023
Repligen Corporation a life sciences company focused on bioprocessing technology leadership, announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technolog...
Alloy Therapeutics | December 10, 2021
Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire ...
AbCellera and Versant Ventures | July 28, 2022
AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships.
Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE